The safety of available treatments options for neuroendocrine tumors

• Published in: Expert opinion on drug safety Vol. 16; no. 10; p. 1149
• Main Authors: Faggiano, A, Lo Calzo, F, Pizza, G, Modica, R, Colao, A
• Format: Journal Article
• Language: English
• Published: England 03.10.2017
• Subjects: Animals; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Drug Design; Humans; Molecular Targeted Therapy - adverse effects; Neuroendocrine Tumors - pathology; Neuroendocrine Tumors - therapy; Radioisotopes - administration & dosage; Radioisotopes - adverse effects; Receptors, Peptide - metabolism; Somatostatin - analogs & derivatives; PRRT; targeted therapy; Neuroendocrine neoplasm; somatostatin analogues; chemotherapy; safety

Neuroendocrine neoplasms (NEN) represent a heterogeneous group of malignancies generally characterized by low proliferation and indolent course. However, about half of the newly diagnosed cases are metastatic and require long-term systemic therapies. Areas covered: This review revises the literature...